The product remains on the market AMAG has 15 days to respond to the FDA AMAG continues to expect its recently announced tender offer and merger to close in November 2020 WALTHAM, Mass., October 5, 2020 — AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it received a notice from the U.S. Food and Drug Administration… More

Addition of AMAG’s category leading treatments positions Covis to become a global market leader of therapeutic solutions for life-threatening conditions and chronic illnesses  Covis will commence a tender offer to acquire all the outstanding shares of AMAG for a purchase price of $13.75 per share in cash, or approximately $647 million, including debt obligations expected… More

Agreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties    Collaboration further advances the development of ciraparantag WALTHAM, Mass. and AMSTERDAM, The Netherlands, July 23, 2020 — AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and Norgine B.V., a leading European specialist… More

Data from two Phase 2 randomized, placebo-controlled, dose-ranging studies using ciraparantag demonstrate efficacy and safety in the reversal of apixaban and rivaroxaban  WALTHAM, Mass., July 12, 2020 — AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced the poster presentation of data from two Phase 2 randomized, placebo-controlled, dose ranging studies which showed safety and efficacy of ciraparantag reversing… More

Company initiates CFO & COO succession plan; appoints internal seasoned finance leader as interim CFO Anthony Casciano assumes expanded role as AMAG’s COO WALTHAM, Mass., June 11, 2020— AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Edward (Ted) Myles, Chief Financial and Chief Operating Officer, is leaving the Company. Brian Piekos, Senior Vice President of Finance,… More

AMAG PHARMACEUTICALS COMPLETES SALE OF ITS RIGHTS TO INTRAROSA® TO MILLICENT PHARMA FOR UP TO $125 MILLION Transaction allows AMAG to advance its strategic focus on Feraheme, Makena and its pipeline, consistent with previously announced plans  Millicent Pharma uniquely positioned to drive revenue growth of Intrarosa WALTHAM, Mass., May 21, 2020 — AMAG Pharmaceuticals, Inc. (NASDAQ:… More

AMAG PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Feraheme® (ferumoxytol injection) posts strong first quarter results Company implements a workforce reduction of approximately 30 percent or 140 positions,as part of a planned decrease in operating expenses Conference call scheduled for 8:00 a.m. ET today WALTHAM, MA (May 11, 2020) AMAG Pharmaceuticals,… More

WALTHAM, Mass., April 28, 2020 – AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its Board of Directors has appointed Scott Myers as AMAG’s President and Chief Executive Officer, and member of the Board, effective immediately. Mr. Myers succeeds William Heiden, who is stepping down from such roles in light of Mr. Myers’ appointment. “Scott… More

AMAG PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE Conference call scheduled for 8:00 a.m. EST today   WALTHAM, Mass., (March 4, 2020) AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2019. Total revenues for the full year of 2019 totaled $327.8 million, including record revenue of $167.9 million from… More

AMAG Pharmaceuticals Announces Leadership Transition, Results of Strategic Review to Unlock Shareholder Value and Financial Update Initiating CEO transition plan Divesting Intrarosa® and Vyleesi®  2020 financial guidance reflects reduction in annual operating expenses of more than  $100M and a return to positive adjusted EBITDA   WALTHAM, Mass., January 9, 2020 – AMAG Pharmaceuticals, Inc. (NASDAQ:… More